+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Mallinckrodt crashes 34% after saying it might file for Chapter 11 bankruptcy due to opioid litigation

Aug 5, 2020, 00:29 IST
Business Insider
FILE- In this July 1, 2013 file photo, is the exterior of the Mallinckrodt Pharmaceuticals office in St. Louis. The generic drugmaker Mallinckrodt has a tentative $1.6 billion deal to settle lawsuits over its role in the U.S. opioid crisis, it announced Tuesday, Feb. 25, 2020. The deal is intended to end hundreds of lawsuits faced by the company over opioids. (Whitney Curtis/AP Images for Mallinckrodt, File)Associated Press
  • Mallinckrodt crashed as much as 34% on Tuesday after the pharmaceutical company said it was exploring the possibility of filing for Chapter 11 bankruptcy due to a number of factors including litigation related to its sale of opioids.
  • Mallinckrodt is in the midst of a $1.6 billion settlement for its sale of opioids, and is also on the hook for a $650 million bill to Medicaid related to its Acthar Gel product.
  • "Looking ahead, we expect our current challenges to continue in the back half of the year," CEO Mark Trudeau said.
  • Mallinckrodt shares are down 58% year-to-date.
  • Visit Business Insider's homepage for more stories.
Advertisement

Mallinckrodt investors may be left holding the bag after the pharmaceutical company said in its second quarter earning release that it was exploring strategic options with external advisers that include filing for Chapter 11 bankruptcy.

Mallinckrodt plummeted as much as 34% to $1.48 in Tuesday trades.

While the pharmaceutical company posted earnings that beat analyst estimates, that wasn't enough to offset the challenges the company is facing due to its opioid litigation settlement, its Acthar Gel medicaid repayment issue, and its high debt levels.

In February, Mallinckrodt said it reached an "agreement in principle" for a global opioid settlement that would entail the company making structured payments over a period of eight years totaling $1.6 billion.

Read more: MORGAN STANLEY: The government's recession response has the stock market heading for a massive upheaval. Here's your best strategy to capitalize on the shift.

Advertisement

On top of that, in March, a federal judge said the company was on the hook to pay back Medicaid $650 million for its Acthar Gel, due to claims that Mallinckrodt underpaid for the drug for years and overcharged Medicaid.

Acthar Gel is used to treat multiple sclerosis and cost Medicaid upward of $150,000 per patient, despite a cheaper alternative being available for $800. In a lawsuit, a subsidiary of Mallinckrodt was accused of bribing doctors to sell Acthar.

Mallinckrodt acquired Acthar Gel when it bought Questcor in 2014.

Finally, Mallinckrodt has an immense pile of debt to address. At the end of the quarter, the company had $5.3 billion in outstanding debt, and paid $64.2 million in interest debt. Mallinckrodt's market cap was just $141 million as of Tuesday, according to data from YCharts.com.

Read more: 100 deals and $1 million in profit a year: Here's how Mike Simmons made a simple change to his real-estate investing strategy that took him from small-time house flipper to full-fledged mogul

Advertisement

Mallinckrodt CEO Mark Trudeau said, "looking ahead, we expect our current challenges to continue in the back half of the year."

Mallinckrodt shares are down 58% year-to-date.

Markets Insider

You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article